Entity

Time filter

Source Type

Jeddah, Saudi Arabia

Bazarbashi S.,King Faisal Specialist Hospital And Research Center | Al Othman K.,King Faisal Specialist Hospital And Research Center | Al Otaibi M.,King Faisal Specialist Hospital And Research Center | Abusamra A.,Princess Norah Oncology Center | And 8 more authors.
Urology Annals | Year: 2011

In this report, guidelines for the evaluation, medical and surgical management of renal cell carcinoma is presented. It is categorized according to the stage of the disease using the tumor node metastasis staging system, 7 th edition. The recommendations are presented with supporting evidence level. Source


Emwas A.-H.M.,King Abdullah University of Science and Technology | Al-Talla Z.A.,King Abdullah University of Science and Technology | Guo X.,King Abdullah University of Science and Technology | Al-Ghamdi S.,Princess Norah Oncology Center | Al-Masri H.T.,Taibah University
Magnetic Resonance in Chemistry | Year: 2013

Copper is an essential nutrient for the normal development of the brain and nervous system, although the hallmark of several neurological diseases is a change in copper concentrations in the brain and central nervous system. Prion protein (PrP) is a copper-binding, cell-surface glycoprotein that exists in two alternatively folded conformations: a normal isoform (PrPC) and a disease-associated isoform (PrPSc). Prion diseases are a group of lethal neurodegenerative disorders that develop as a result of conformational conversion of PrPC into PrPSc. The pathogenic mechanism that triggers this conformational transformation with the subsequent development of prion diseases remains unclear. It has, however, been shown repeatedly that copper plays a significant functional role in the conformational conversion of prion proteins. In this review, we focus on current research that seeks to clarify the conformational changes associated with prion diseases and the role of copper in this mechanism, with emphasis on the latest applications of NMR and EPR spectroscopy to probe the interactions of copper with prion proteins. Copyright © 2013 John Wiley & Sons, Ltd. Source


Kalaycio M.,Cleveland Clinic | Bolwell B.,Cleveland Clinic | Rybicki L.,Cleveland Clinic | Absi A.,Princess Norah Oncology Center | And 5 more authors.
Bone Marrow Transplantation | Year: 2011

Evidence suggests an advantage for TBI over BU as a component of conditioning regimens for allogeneic hematopoietic cell transplant in patients with ALL. We have employed both TBI and BU for conditioning in ALL and reviewed our experience to compare outcomes. From July 1989 to June 2008, we identified 86-adult ALL patients treated with either a TBI- or BU-based regimen and transplanted with either a well-matched sibling or unrelated donor. Data including demographics, immunophenotype, disease status and cytogenetic risk were examined by Cox proportional hazards analysis. Patients treated with TBI were older (median age 40 vs 33 years; P=.018), had a higher-risk cytogenetic profile (P=.010), were more often transplanted using an unrelated donor (P=.038) and were treated more recently (P<0.010). There was a significant improvement in EFS (P=.046), and a trend to improved OS (P=.08) in patients treated with TBI compared with those treated with BU. However, the advantage for TBI could not be confirmed by multivariable analysis where only disease status retained statistical significance. © 2011 Macmillan Publishers Limited All rights reserved. Source


Baugh G.,Coventry University | Al-Alawi T.,Princess Norah Oncology Center | Fletcher C.L.,Coventry University | Mills J.A.,Coventry University | Grieve R.J.,Coventry University
British Journal of Radiology | Year: 2011

Objectives: In the UK, the treatment of patients with mycosis fungoides using total skin electron (TSE) beam therapy is undertaken using a number of different irradiation techniques. As part of a review of these techniques, a comparative set of measurements would be useful to determine how the techniques differ in terms of dose distribution. A dose penetration intercomparison method that could be used as part of such a study is presented here. Methods: The dose penetrations for six treatment techniques currently or recently used in four centres in the UK were measured. The variation of dose with skin depth was measured in a WT1 solid water mid-torso phantom. The phantom is portable and suitable to be used in all the techniques. It is designed to hold four small radiochromic film dosemeters to investigate the variation in dose around the mid-torso. For each treatment technique, the phantom was irradiated using the clinical set-up. Results: The phantom performed well and was able to measure dose penetration and the uniformity of penetration for several treatment techniques. Conclusion: These preliminary results demonstrate that there is some variation in dose distribution between different TSE treatment techniques and that the phantom could be used in amore comprehensive intercomparison. The results are not intended to demonstrate comprehensively the range of penetration that can be achieved in clinical practice as, for one of the treatment techniques, the penetration is customised for the extent of the disease. © 2011 The British Institute of Radiology. Source


Abusamra A.,Urology Section | Murshid E.,Oncology Center | Kushi H.,Princess Norah Oncology Center | Alkhateeb S.,King Saud bin Abdulaziz University for Health Sciences | And 7 more authors.
Urology Annals | Year: 2016

This is an update to the previously published Saudi guidelines for the evaluation, medical, and surgical management of patients diagnosed with prostate cancer. It is categorized according to the stage of the disease using the tumor node metastasis staging system 7th edition. The guidelines are presented with supporting evidence level, they are based on comprehensive literature review, several internationally recognized guidelines, and the collective expertise of the guidelines committee members (authors) who were selected by the Saudi oncology society and Saudi urological association. Considerations to the local availability of drugs, technology, and expertise have been regarded. These guidelines should serve as a roadmap for the urologists, oncologists, general physicians, support groups, and health care policy makers in the management of patients diagnosed with adenocarcinoma of the prostate to. © 2016 Urology Annals | Published by Wolters Kluwer - Medknow. Source

Discover hidden collaborations